AIM: To assess the correlation between the serum hepcidin-25 level and left ventricular mass index.METHODS: This study was a cross-sectional study conducted between March 2009 and April 2010. Demo-graphic and biochemi...AIM: To assess the correlation between the serum hepcidin-25 level and left ventricular mass index.METHODS: This study was a cross-sectional study conducted between March 2009 and April 2010. Demo-graphic and biochemical data, including the serum hepcidin-25 level, were collected for chronic kidney disease(CKD) patients. Two-dimensional echocardiography was performed to determine the left ventricle mass(LVM), left ventricular mass index(LVMI), interventricular septum thickness(IVSd), left ventricle posterior wall thickness(LVPW), right ventricular dimension(RVD), left atrium(LA) and ejection fraction(EF).RESULTS: A total of 146 patients with stage 1 to 5 CKD were enrolled. Serum hepcidin-25 levels were 16.51 ± 5.2, 17.59 ± 5.32, 17.38 ± 6.47, 19.98 ± 4.98 and 22.03 ± 4.8 ng/mL for stage 1 to 5 CKD patients, respectively. Hepcidin-25 level was independently predicted by the serum ferritin level(β = 0.6, P = 0.002) and the estimated glomerular filtration rate(β =-0.48, P = 0.04). There were negative correlations between the serum hepcidin level and the LVM and LVMI(P = 0.04 and P = 0.005, respectively). Systolic blood pressure(BP) was positively correlated with the LVMI(P = 0.005). In the multivariate analysis, a decreased serum hepcidin-25 level was independently associated with a higher LVMI(β =-0.28, 95%CI:-0.48--0.02, P = 0.006) after adjusting for body mass index, age and systolic BP. CONCLUSION: A lower serum hepcidin level is associated with a higher LVMI in CKD patients. Low hepcidin levels may be independently correlated with unfavorable cardiovascular outcomes in this population.展开更多
基金Grants from the Department of Health(DOH 97-HP-1103)
文摘AIM: To assess the correlation between the serum hepcidin-25 level and left ventricular mass index.METHODS: This study was a cross-sectional study conducted between March 2009 and April 2010. Demo-graphic and biochemical data, including the serum hepcidin-25 level, were collected for chronic kidney disease(CKD) patients. Two-dimensional echocardiography was performed to determine the left ventricle mass(LVM), left ventricular mass index(LVMI), interventricular septum thickness(IVSd), left ventricle posterior wall thickness(LVPW), right ventricular dimension(RVD), left atrium(LA) and ejection fraction(EF).RESULTS: A total of 146 patients with stage 1 to 5 CKD were enrolled. Serum hepcidin-25 levels were 16.51 ± 5.2, 17.59 ± 5.32, 17.38 ± 6.47, 19.98 ± 4.98 and 22.03 ± 4.8 ng/mL for stage 1 to 5 CKD patients, respectively. Hepcidin-25 level was independently predicted by the serum ferritin level(β = 0.6, P = 0.002) and the estimated glomerular filtration rate(β =-0.48, P = 0.04). There were negative correlations between the serum hepcidin level and the LVM and LVMI(P = 0.04 and P = 0.005, respectively). Systolic blood pressure(BP) was positively correlated with the LVMI(P = 0.005). In the multivariate analysis, a decreased serum hepcidin-25 level was independently associated with a higher LVMI(β =-0.28, 95%CI:-0.48--0.02, P = 0.006) after adjusting for body mass index, age and systolic BP. CONCLUSION: A lower serum hepcidin level is associated with a higher LVMI in CKD patients. Low hepcidin levels may be independently correlated with unfavorable cardiovascular outcomes in this population.
